Translational Research Services
Oncology
Key Facts
About Cypre
Cypre is a private, preclinical-stage biotech platform company founded in 2020, operating in the AI/Machine Learning and Drug Delivery sectors with a focus on oncology. Its core offering is a sophisticated 3D tumor microenvironment (TME) platform, built on proprietary VersaGel® and Symphony® hydrogels, designed to reduce reliance on animal studies and improve clinical predictability for therapies like ADCs, T-cell engagers, and immunotherapies. The company employs a partnership-driven business model, offering both translational research services and integrated drug discovery collaborations to generate IND-ready data packages for its clients. Cypre is positioned to capitalize on the growing demand for human-relevant, high-throughput preclinical models amid increasing regulatory scrutiny of animal data.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |